~~<i id='2E8F9BE8B3'><strike id='2E8F9BE8B3'><tt id='2E8F9BE8B3'><pre id='2E8F9BE8B3'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：Wikipedia 2025-09-02 08:12:15 - browse：221

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Publishing genetic code of viruses could cause disaster

focus

leisure time

focus

explore

focus

AdobeWASHINGTON—TheFoodandDrugAdministration’stopcancerdrugregulatordoesn’talwaysaskforpermissionbef

WSS

Hospitals, health systems can help patients avoid medical debt

NIH chief: government has fallen behind pharma on clinical trials

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

CDC: Cases of alpha

How state and local governments are sidelining science

Ford recalls 870K F

hotspot

entertainment

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Duchenne breakthrough therapy leaves behind pioneering families

Trader Joe's recalls 10K cases of broccoli cheddar soup over potential foreign material

Wildfire smoke exposes gaps in outdoor worker protections

Ford recalls 870K F

Walensky prepares to leave CDC — and Congress — behind

Experimental asthma app from Apple and Anthem shows promise

Cancer drug shortages should be causing more outrage

NIH chief: government has fallen behind pharma on clinical trials

focus

FDA reorg will put new emphasis on investigations, sources say

NIH chief: government has fallen behind pharma on clinical trials

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Readout Newsletter: Zepbound, Valneva's vaccine, and more

White House drug czar issues call for 'recovery

leisure time

focus

explore

focus